ProfileGDS5678 / 1430011_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 35% 34% 34% 33% 33% 35% 37% 34% 33% 34% 34% 33% 34% 34% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8274635
GSM967853U87-EV human glioblastoma xenograft - Control 22.7757934
GSM967854U87-EV human glioblastoma xenograft - Control 32.7784234
GSM967855U87-EV human glioblastoma xenograft - Control 42.6984433
GSM967856U87-EV human glioblastoma xenograft - Control 52.7043733
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8795335
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9146537
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7549334
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7252433
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7522834
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.776334
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7239633
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7779334
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7682834